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Introduction
Epidemics of ‘convulsive ergotism’ were widespread and well 
described east of the Rhine river from 1085 to 1927.1 Given 
that ergot alkaloids, a known contaminant of human cultivated 
grains, are now recognised to induce serotonin syndrome (SS), 
this suggests that the syndrome may have been a public health 
problem long before its more recent ‘discovery’ as a complica-
tion of modern pharmacology.1
5-Hydroxytryptamine (5-HT), a monoamine neurotrans-
mitter, first recognised in 1948,2 has a wide range of functions 
in the central nervous system (CNS), including modulation 
of attention, cognition, behaviour, memory, and thermoregu-
lation, as well as in the peripheral nervous system (PNS), 
where it regulates, for example, gastrointestinal (GI) motility, 
uterine contraction, vasoconstriction, and bronchoconstric-
tion.3 The first report of a clinical picture consistent with 
what nowadays is termed SS was in 1960,4 which described 
the coadministration of L-tryptophan (the substrate of the 
rate-limiting enzyme, tryptophan hydroxylase [TPH], in the 
biochemical synthesis of serotonin) with a monoamine oxi-
dase inhibitor (MAOI) inducing delirium. The first use of the 
term SS came 20 years later, describing the characteristic fea-
tures in rats of tremor, rigidity, hypertonicity, hind-limb 
abduction, Straub tail, lateral head shaking, hyperactivity to 
auditory stimuli, myoclonus, generalised seizures, and various 
autonomic responses such as salivation, penile erection, and 
ejaculation.5 Two years later, the first contemporaneous case 
in humans was reported by Insel et al,6 followed by numerous 
case reports and reviews.7-11
The aim of this review is to summarise the pathophysiology 
of SS in relation to the 5-HT signalling pathway in the CNS, 
clinical features, diagnosis, management, and prognosis.
Epidemiology
Serotonin syndrome is observed across the full range of age 
groups, from neonates all the way through to the elderly, with 
an increasing incidence likely to represent the increasing use 
of serotonergic drugs in clinical practice.7,12,13 The percentage 
of adults taking antidepressants in the United States nearly 
doubled between 1999 and 2010, increasing from 6% to 
10.4%.14 In 2016, the Toxic Exposure Surveillance System, 
which receives case descriptions from emergency depart-
ments, inpatient settings, and office-based practices, reported 
54 410 incidences of exposures to selective serotonin reuptake 
inhibitors (SSRIs; 43% of which were single exposures), with 
102 deaths (the ninth most common cause of fatality in drug 
overdoses in the United States in this period). This repre-
sented an 18% increase in cases between 2002 and 2016 and 
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an 8% increase in the number of deaths.15-17 Large case series 
suggest that moderate SS occurs in approximately 15% of 
poisonings with SSRIs.18 A recent study found that close to 
half of U.S. Food and Drug Administration (FDA) Adverse 
Event Reporting System (FAERS) SS reports involved a sin-
gle drug (depending on the diagnostic criteria used), which is, 
perhaps, a little surprising, given the common perception of a 
multidrug aetiology.19
The true incidence of SS, however, is unknown, as is the 
number of cases that are mild, moderate, or severe. There are a 
number of reasons for this: it is a relatively uncommon condi-
tion that cannot be easily picked up in randomised clinical control 
trials,20 and the condition is under-recognised and under-
reported by physicians (85% of general physicians [GPs] were 
not familiar with the condition in one survey,21 and mild cases 
are often dismissed or self-limiting).20
Pathophysiology and Molecular Mechanisms
The serotonin signalling pathway
The cells of the raphe nuclei located in the midline of brain-
stem (from the midbrain to the medulla) are the source of 
neuronal 5-HT in the CNS.22 The 9 raphe nuclei (B1-B9) are 
centred in the reticular formation, and axons from the sero-
tonergic neurons in this region form a neurotransmitter sys-
tem that functionally affects most parts of the CNS. The 
rostral group of nuclei project into multiple cortical and sub-
cortical structures contributing to the regulation of wakeful-
ness, attention, affective behaviour (depression and anxiety), 
sexual behaviour, appetite, thermoregulation, and migraine.22 
The caudal group project into the spinal regions and are 
involved in motor tone as well as nociception.22 In the periph-
ery 5-HT, produced in the enterochromaffin (EC) cells of the 
GI tract, is involved in the regulation of GI motility as well 
a number of roles in vascular biology.22 These include control 
of blood pressure through vasoconstriction or vasodilation 
depending on the expressed receptor type in the vessel wall, 
as well as control of haemostasis and platelet function. 
Serotonin is secreted during platelet activation, playing an 
important role in their aggregation and concomitant vaso-
constriction of the surrounding blood vessels during haemo-
stasis. Platelets lack enzymes to synthesise serotonin,23 and 
are therefore reliant on taking up serotonin from the plasma 
via the serotonin transporter. Selective serotonin reuptake 
inhibitors can inhibit the uptake of serotonin by platelets 
leading to decreased aggregation responses and thereby 
increasing bleeding time.24 For this reason, SSRIs should be 
used in caution in those patients on anticoagulants or at 
higher risk of bleeding. Intriguingly, there is emerging evi-
dence that SSRI treatment may lower myocardial infarction 
risk though their inhibition of platelet aggregation.25,26 The 
occurrence of disseminated intravascular coagulation in 
severe SS27 may be due to an exaggerated platelet aggrega-
tion response driven by excess peripheral serotonin.
The initial and rate-limiting step in the biosynthesis of 
5-HT, the decarboxylation and hydroxylation of the essential 
amino acid tryptophan, is catalysed by TPH.28 There are 2 
isoforms of this enzyme, TPH1 and TPH2, which are highly 
homologous but differ in their kinetic properties and their 
tissue distribution.29,30 Tryptophan hydroxylase 1, the source 
of most peripheral 5-HT, is predominantly expressed in the 
EC cells of the gut and other peripheral tissues, such as the 
pancreas, lung, and adipose tissue, though is also expressed in 
the pineal gland where 5-HT serves as the precursor mole-
cule for melatonin biosynthesis.29,31,32 Tryptophan hydroxy-
lase 2, the source of the central neurotransmitter pool of 
5-HT, is predominantly expressed in the raphe projection 
neurons of the brainstem,29,33 though is also found in the 
myenteric neurons of the gut.32,34 Work with knockout ani-
mals suggests that TPH1 expression in the pineal gland does 
not significantly contribute to the central 5-HT pool,35 and 
similarly, TPH2 expression in the myenteric plexus does not 
significantly contribute to the peripheral 5-HT pool.36 Once 
synthesised from tryptophan, 5-HT is then stored in presyn-
aptic vesicles until it is required for neurotransmission and 
released into the synaptic cleft. Serotonergic signalling is a 
tightly regulated process characterised by a combination of 
feedback loops, multiple reuptake mechanisms, and metabo-
lising enzymes (Figure 1). Depolarisation of the presynaptic 
axon leads to the release of serotonin into the synaptic cleft, 
which leads to multiple downstream effects; activation of 
presynaptic serotonin autoreceptors inhibits exocytosis of 
further vesicles, while binding to postsynaptic 5-HT recep-
tors effects neurotransmission. Serotonergic signalling is ter-
minated primarily by the uptake of 5-HT from the synaptic 
cleft back into the presynaptic neuron. This is accomplished 
predominantly by the serotonin reuptake transporter protein 
(SERT) on the presynaptic membrane, though there is evi-
dence that the plasma membrane monoamine transporter 
(PMAT) may also contribute.37 5-Hydroxytryptamine is then 
metabolised into 5-hydroxyindoleacetic acid (5-HIAA) pri-
marily by monoamine oxidase A (MAO-A).
There are at least 7 families of 5-HT receptors (5-HT1 
to 5-HT7), some of which have multiple subtypes, result-
ing in a total of 14 structurally and pharmacologically dis-
tinct receptors.38
The 5-HT1 receptor family consist of 5 subtypes: 5-HT1A, 
5-HT1B, 5-HT1D, 5-HT1e, and 5-HT1F receptors are 
G-protein-coupled receptors (GPCRs) that signal via the inhi-
bition of adenylate cyclase or G-protein-sensitive K+ channels 
(note that the 5-HT1e receptor is still just recognised as a gene 
product, since no function has been attributed to this receptor 
in native tissue). While a number of clinically used drugs affect 
these receptors, the 5-HT1A receptor provides a pharmacologi-
cal target for the anxiolytic agent, buspirone, which lacks 
potential for dependency. However, 5-HT1B/1D (and possibly 
5-HT1F) receptors are targeted by the antimigraine ‘triptans’, 
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examples of which include sumatriptan and zolmitriptan 
(which are also used for cluster headaches).
The 5-HT2 receptor family consists of 3 members: 
5-HT2A, 5-HT2B, and 5-HT2C receptors that are excitatory 
GPCRs signalling via Gq to activate, for example, phospholi-
pase C to generate Inositol 1,4,5-triphosphate (IP3) and dia-
cyl glycerol. Many antipsychotic drugs at relevant clinical 
concentrations interact with 5-HT2 receptors, with antago-
nism of the 5-HT2A receptor likely to contribute to therapeu-
tic effects (eg, risperidone). More recently (2012), the 5-HT2C 
receptor has been targeted selectively with the agonist, lorca-
serin, to treat obesity by reducing food intake (although not 
yet approved in Europe).
The 5-HT3 receptor is a ligand-gated ion channel of the 
cys-cys loop class that conducts Na+/K+/Ca2+; this excitatory 
receptor is expressed predominantly by  neurons and is respon-
sible for initiating emesis following aggressive anticancer ther-
apy (that releases copious quantities of 5-HT from the EC GI 
tract) such that antagonists such as ondansetron offer effective 
antiemetic treatment. The 5-HT3 receptor also mediates pro-
kinetic activity of the GI tract – as occurs in irritable bowel 
syndrome (IBS) or carcinoid patients; for both patient cohorts, 
5-HT3 receptor antagonists are beneficial to reduce diarrhoea, 
although currently, they are only indicated for IBS (and only in 
some territories like the United States and Japan).
The 5-HT4 receptor is a GPCR that promotes adenylate 
cyclase activity via Gs. The receptor increases gastric motility 
by increasing the activity of, for example, cholinergic  neurons 
in the GI tract and is activated by some drugs used to reverse 
constipation (eg, prucalopride).
The 5-HT5 receptors are GPCRs and the family has 2 
members: 5-HT5A and 5-HT5b receptors. The latter receptor is 
not functional in humans due to the insertion of a stop codon 
into the gene that results in a truncated protein. Little is known 
about the 5-HT5A receptor, and it is not actively targeted for 
therapeutic benefit.
The 5-HT6 and 5-HT7 receptors are both GPCRs that 
couple via Gs to promote cAMP synthesis via adenylate cyclase. 
There has been much interest in these as potential clinical tar-
gets, largely due to the known interaction of a wide range of 
antipsychotic and antidepressant drugs that antagonise these 
receptors. However, to date, no clinically used drug selectively 
targets either receptor.
Further structural and functional diversity occurs in 5-HT 
receptors through allelic polymorphisms, splice variants, and 
the formation of receptor heterodimers.34,39
Pharmacology of serotonin and cellular toxicity
Serotonin syndrome can result from agonism (either from 
increased concentrations of 5-HT or medications that act 
directly as receptor agonists), and/or antagonism, of varying 
combinations of the 5-HT receptor subtypes. Stimulation of 
the postsynaptic 5-HT1A and 5-HT2A receptors has been 
implicated in SS, but no single receptor is likely to be solely 
responsible. The classical view, mainly supported by evidence 
from animal studies (with few studies in humans), is that the 
life-threatening effects of SS, in particular, severe hypertonicity 
and hyperthermia, are primarily mediated by the activation of 
5-HT2A receptors at higher serotonin concentrations.18 The 
5-HT1A receptors, which have a higher affinity for 5-HT and 
are therefore likely to be nearly fully occupied at much lower 
extracellular 5-HT concentrations, possibly contribute to some 
of the milder symptoms including anxiety and hyperactivity.40 
This may provide a pharmacological explanation for why severe 
SS is usually only seen with particular combinations of drug 
classes, in particular MAOIs (that increase 5-HT concentra-
tion in the synapse) and SSRIs (that modulate 5-HT receptor 
signalling at the postsynaptic membrane in addition to inhibit-
ing serotonin reuptake via the SERT).18,41,42
Recently, a bioinformatics approach has demonstrated an 
association between second-generation antipsychotics (SGAs) 
Figure 1. Mechanisms of serotonin syndrome: (1) Increased levels of 
L-tryptophan will lead to increased levels of endogenous 5-HT; a step 
catalysed by the enzyme tryptophan hydroxylase 2 (TPH2). (2) 
Increased presynaptic concentrations of 5-HT due to inhibition of 
serotonin metabolism by MAOIs. (3) Increased 5-HT release by drugs 
including amphetamines and their derivatives, cocaine, MDMA, and 
levodopa. (4) Direct or indirect activation of postsynaptic 5-HT1A 
receptors. (5) Direct or indirect antagonism of postsynaptic 5-HT2A 
receptors is thought to enhance the effect of 5-HT1A agonists. (6) 
Increased synaptic levels of 5-HT due to inhibition of the SERT by 
reuptake inhibitors such as SSRIs, and TCAs. MAOIs indicate 
monoamine oxidase inhibitors; MDMA, 3,4-methylenedioxy-
methamphetamine; SERT, serotonin reuptake transporter protein; 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic 
antidepressant.
4 International Journal of Tryptophan Research 
and SS.43 Counter to the classical view that 5-HT2A agonism is 
a significant contributor to severe SS, the authors have sug-
gested a potential role for 5-HT2A antagonism in concert with 
5-HT1A agonism as a common mechanism that may explain 
the SGA-SS association. It is this effect on the serotonergic 
system that distinguishes the SGAs (‘atypical’ antipsychotics) 
from the older ‘typical’ antipsychotics (butyrophenones, diphe-
nylbutylpiperidines, and phenothiazines) that predominantly 
antagonise D2 dopaminergic receptors and are not associated 
with SS. They postulate that in the presence of SERT inhibi-
tion, 5-HT levels are increased throughout serotonergic syn-
apses, and 5-HT2A antagonism then shunts elevated levels of 
5-HT to the co-localised 5-HT1A receptor.44,45 This selective 
activation of the 5-HT2A receptor not only appears to increase 
its sensitivity to 5-HT46-48 but may also enhance the effects of 
5-HT1A agonists.49,50 In addition, there is evidence that 
5-HT2A receptor antagonists may elevate 5-HT neurotrans-
mission via a disinhibitory feedback loop, through inhibition of 
local gamma-aminobutyric acid (GABA) interneurons in the 
dorsal raphe nucleus.51 This association (and potential mecha-
nistic explanation) is reinforced by a recent meta-analysis of SS 
cases, in which 3% (10/299) of cases were associated with 
SGAs as the decisive triggering factor. Eight of these cases 
occurred in combination with antidepressants and 2 in the 
context of an SGA swap. Interestingly, in this study, 45.4% of 
the SS cases had rigidity/hypertonicity, and 14.0% of cases had 
rhabdomyolysis and symptoms also commonly associated with 
neuroleptic malignant syndrome (NMS).20 Whether 5-HT2A 
receptor antagonism in concert with 5-HT1A agonism plays a 
role in all cases of SS or is the exception in the case of SGAs 
remains to be determined.
An additional question is whether other neurotransmitters 
play a role, particularly in the development of severe SS. A full 
review of the large body of evidence in this area is beyond the 
scope of this review, though it is important to emphasise that 
active research is ongoing, and many questions remain to be 
definitively answered. In animal models, it has been shown that 
5-HT can cause the release of noradrenaline from the anterior 
hypothalamus, a neurotransmitter known to cause CNS hyper-
excitability, which may correlate with the clinical outcome.52-54 
Gamma-aminobutyric acid, N-methyl-D-aspartate (NMDA), 
and dopamine may also play a role through their recruitment, 
in addition to direct serotonin stimulation, in severe SS.52,55 A 
recent study using a systematic bioinformatics approach to 
analyse off-target effects of the drugs most commonly involved 
in SS supports the hypothesis that multiple neurotransmitter 
pathways may be recruited in addition to direct serotonin stim-
ulation in severe SS.19 As well as highlighting the importance 
of SERT inhibition (46/71 serotonergic drugs interacted with 
this protein), there was a higher than expected association of 
SS cases in the triple receptor drug cohort (drugs that interact 
at SERT, norepinephrine transporter [NET], and muscarinic 
receptors).19 Off target receptor activity may help to explain 
the differences in the severity of the syndrome as well as the 
spectrum of clinical features. These findings raise the possibil-
ity that when the offending drug (or combination of drug 
classes) has (have) both antidopaminergic and serotonergic 
activity,20 the resulting toxidrome may share features of both 
SS and NMS.
Drugs commonly associated with SS
A wide range of drug types and combinations have been impli-
cated in SS, with the final common pathway thought to involve 
a net increase in serotonergic neurotransmission. The main 
drug classes classically implicated in SS can be divided into 
serotonin precursors, inhibitors of serotonin reuptake from the 
synaptic cleft, inhibitors of serotonin metabolism, direct sero-
tonin receptor agonists, and drugs that sensitise serotonin 
receptors (Table 1). As discussed in the previous paragraph, 
there is evidence that serotonin antagonism (in particular 
5-HT2A antagonism) may also play a role, based on the 
observed association between SGAs and SS.43
Pharmacokinetic drug interactions are also implicated 
through the inhibition of the cytochrome P450 pathway, a path-
way that SSRIs themselves inhibit (in particular CYP2D6 and 
CYP3A4.56,57 At least 25 serotonergic drugs are metabolised by 
the cytochrome P450 pathway,19 and a recent study has shown 
that 50% of the top 20 drugs associated with SS have known 
pharmacokinetic interactions in which coadministration of 
cytochrome P-450 inhibitors may elevate drug concentrations to 
toxic levels. These drugs collectively were shown to participate 
in > 70% of all the reported SS reports in their study.19 Examples 
include the concomitant use of SSRIs and tramadol,12,58 SSRIs 
and ciprofloxacin,59 as well as of citalopram and fluconazole.60
Although SS has been described after overdose of a single 
drug,61 and occasionally from increasing therapeutic doses in 
susceptible individuals, this only usually results in mild to mod-
erate SS.4,13,62 Severe SS usually only occurs with the concomi-
tant administration of 2 or more serotonergic drugs (even at 
therapeutic doses) (Table 2), with the combination of seroton-
ergic drugs with MAOIs being especially dangerous, causing 
serious adverse outcome including death.8,41,42
Taken together, these observations are consistent with the 
hypothesis that SS is a dose-dependent spectrum of adverse 
effects mediated by a combination of elevation of endogenous 
intrasynaptic or extrasynaptic serotonins and direct or indirect 
activation of 5-HT receptors.63 However, the fact that different 
patients present with SS at differing drug dosages and/or com-
binations suggests that there may also be underlying genetic and 
pharmacodynamic factors that modulate susceptibility.11 Genetic 
factors could include polymorphisms in the CYP450 pathway,64 
the SERT gene,65 as well as the 5-HT2 receptor.18,13,66
The role of novel psychoactive substances in SS
Novel psychoactive substances (NPSs), commonly described as 
novel, designer, or synthetic drugs,67 are a growing public 
health concern due their increasing availability and use. They 
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are often synthetic derivatives and analogues of known com-
pounds currently prohibited under current drug laws, such as 
amphetamines and cannabis.68 The ease of synthesising and 
speed of technological innovation has led to an explosion in the 
number of newly identified NPS, creating significant chal-
lenges to the regulatory authorities as well as to the research 
community investigating the pharmacology of these agents.69-72 
In 2014, 101 newly identified NPSs were reported to the 
European Union early warning system,71 and by 2017, the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) was monitoring more than 620 NPSs,73 with 1 
new NPS being identified each week. There is currently lim-
ited population-based data detailing NPS use, and a wide range 
of estimates based on the data that does exist. A 2014/15 
Table 1. Drugs associated with serotonin syndrome.
MECHANISM DRUgS ASSOCIATED WITH SS
Increased 5-HT 
synthesis
Dietary supplements: Tryptophan
Inhibition of 
5-HT 
metabolism
MAOIs: include safinamide, selegiline, rasagiline, phenelzine, tranylcypromine, isocarboxazid, moclobemide, 
linezolid, tedizolid, methylene blue, procarbazine, and Syrian rue [Peganum harmala and harmine]
Herbal supplements: St. John’s wort [Hypericum perforatum]
DNRIs: include buspirone
 
Increased 
release of 5-HT
Drugs of abuse: cocaine, MDMA (‘Ecstasy’)
Amphetamine and derivatives: include phentermine, fenfluramine, and dexfenfluramine
 
Cold remedies: dextromorphan
Activation of 
5-HT1 receptors
DNRIs: buspirone
Triptans: include almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan
Ergot derivatives: include ergotamine and methylergonovine
Opiates: fentanyl and meperidine
Drugs of abuse: LSD
Antidepressants/mood stabilisers: mirtazapine, trazodone, and lithium
Antagonism of 
5-HT2A receptors
Second-generation antipsychotics: include quetiapine, risperidone, olanzapine, clozapine, and 
aripiprazole20,43
Inhibition of 
5-HT uptake 
from synaptic 
cleft
Amphetamine and derivatives: include phentermine, fenfluramine, and dexfenfluramine
Drugs of abuse: cocaine and MDMA (‘Ecstasy’)
SSRIs: include citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline
SNRIs: include venlafaxine, duloxetine, milnacipran, and desvenlafaxine
TCAs: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, 
protriptyline, and trimipramine
DNRIs: include buspirone
Opioids: include levomethorphan, levorphanol, meperidine, methadone, pentazocine, pethidine, tapentadol, 
and tramadol
5-HT3 receptor antagonists: ondansetron, and granisetron
Antihistamines: chlorphenamine
Herbal supplements: St. John’s wort [Hypericum perforatum]
Cold remedies: dextromorphan
Abbreviations: 5-HT, 5-hydroxytryptamine; SS, Serotonin syndrome; MAOI, monoamine oxidase inhibitor; DNRI, dopamine-norepinephrine uptake inhibitor; MDMA, 
3,4-methylenedioxy-methamphetamine; LSD, lysergic acid diethylamide; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; 
TCA, tricyclic antidepressant.
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Crime Survey for England and Wales estimated that 0.9% of 
16 to 59 year olds are users, with this figure rising to 2.8% in 
the 16- to 24-year-old age group.74 This compared to 6.7% for 
cannabis, 2.4% for cocaine, 1.7% for 3,4-methylenedioxy-
methamphetamine (MDMA), and 0.6% amphetamines.74 
Another annual survey reported that 10% of United Kingdom 
and 22% of Irish 15 to 24 year olds had experimented with 
NPS.75 A recent review of the presence of NPS in HM 
Coroners or Police Forces cases in the United Kingdom, 
showed that over a 2-year period, NPSs were detected in 203 
cases; the presence of multiple NPSs and/or other stimulants 
was a particular feature in some cases, and of the drug deaths 
(58% of total cases), 7% were solely due to an NPS.76
Classification of these compounds can be based either on 
their psychotropic effects (stimulant, empathogen/enactogen, 
hallucinogen, and dissociative)68,77 or based on their chemical 
family (phenethylamines, amphetamines, cathinones, pipera-
zines, pipradrols/piperidines, aminoindanes, benzofurans, and 
tryptamines).78 Most of these drugs interact with the mono-
amine neurotransmitter transporters (dopamine transporter 
[DAT], SERT, NET), in the CNS to varying degrees altering 
levels of dopamine, serotonin, and noradrenaline, and there-
fore, in overdose can produce a range of overlapping toxi-
dromes (serotonergic, sympathomimetic, and so on) 
depending on their particular receptor specificities. The rela-
tive dopaminergic to serotonergic properties in vitro (dopa-
mine/serotonin transporter inhibition ratio) of an NPS have 
been postulated as a useful marker for its potential clinical 
psychotropic and acute toxic effects;79 MDMA-like agents 
are associated with a high serotonin:dopamine transporter-
inhibition ratio, whereas more pure amphetamine-like agents 
have a higher dopamine:serotonin transporter-inhibition 
ratio.68 This ratio, however, does not capture the full complex-
ity of action of these NPSs, not least because it does not 
account for the noradrenergic effects that can be a predomi-
nant feature in particular with the amphetamine, cathinone, 
and aminoindane drug classes.
The empathogenic NPSs are of particular interest in rela-
tion to SS, given that the effects of MDMA, the prototypic 
empathogen, are generally considered to depend on its sero-
tonergic effects (driving increased 5-HT efflux into the syn-
aptic cleft).68,80 3,4-Methylenedioxy-methamphetamine has 
been consistently associated with serotonergic toxicity and 
SS.81-83 In addition, MDMA and other amphetamine-like 
drugs such as fenfluramine, are direct agonists of the 5-HT2B 
receptor and may cause fibrosis in the periphery (eg, cardiac 
valvulopathy). Therefore, NPS drug classes (cathinones, ami-
noindanes, piperazines, and phenylethylamines) that have 
similar empathogenic effects to MDMA are likely to simi-
larly lead to increased levels of serotonin, and a similar risk 
of SS at higher doses. In support of this, there are numerous 
case reports, as well as toxicity studies in animal models, 
documenting the development of SS with abuse of those 
drug classes with a high serotonin:dopamine transporter-
inhibition ratio (cathinones,84,85 phenylethylamines,67,86-90 
aminoindanes,91-93 as well as mixed serotonergic/sympatho-
mimetic toxidromes in those where the dopamine:serotonin 
transporter-inhibition ratio is higher).77,86,94
Table 2. Reported drug combinations causing moderate to severe serotonin syndrome.7,8,11
DRUg CLASS DRUg COMBINATIONS
MAOIs MAOIs + SSRIs or SNRIs or TCAs or opiates
Imipramine + tranylcypromine
Phenelzine + meperidine
Methylene blue + clomipramine or paroxetine
SSRIs SSRIs + MAOIs or TCAs or SNRIs or opiates or triptans
Fluoxetine + carbamazepine or phentermine or fentanyl
SNRIs SNRIs + TCAs or MAOIs or opiates or triptans
Venlafaxine + lithium or calcineurin inhibitors or mirtazapine or tranylcypromine
Other antidepressants Mirtazapine + SSRIs
Trazadone + amitriptyline + lithium
Opiates Opiates + MAOIs or SSRIs or SNRIs or triptans
Cold remedies Dextromorphan + SSRIs or TCAs or atypical antipsychotics
Atypical antipsychotics Olanzapine + citalopram and lithium
Risperidone + paroxetine or fluoxetine
Antibiotics/antifungals Linezolid + SSRIs or tapentadol
Fluconazole + citalopram
Ciprofloxacin + methadone + venlafaxine
Abbreviations: MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic 
antidepressant.
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The difficulty in identifying the true levels of usage of these 
NPSs, as well the associated clinical presentation in acute tox-
icity, is highlighted in a recent study that reviewed what data 
are currently being collected in Europe on emergency depart-
ment presentations with acute toxicity related to NPSs and 
classical drugs of abuse.95 This revealed that of the 27 countries 
included, more than half (52%) did not perform any registra-
tion of such data, while only 37% collected systematic clinical 
data on NPS at a national level. The lack of knowledge about 
these NPSs is reflected in the lack of confidence among the 
health care team in managing acute NPS toxicity in the emer-
gency setting.96 Current research into the effects of these NPSs, 
however, suggests that toxicity associated with these agents 
broadly falls into 3 broad groups similar to that seen with clas-
sical drugs (stimulant, hallucinogenic, and depressant). Future 
training should therefore focus on recognising and managing 
the particular toxidrome(s) that an individual presents with, 
rather than the particular agent (which is often never identi-
fied) that the patient has taken.94,97 The reader is directed to 
the recent review on the practical management of toxicity asso-
ciated with NPS.94
Clinical Features
Given that the diagnosis of SS is made solely on clinical 
grounds, a detailed history and comprehensive physical and 
neurological examinations are essential. The presentation is 
highly variable ranging from mild symptoms to a severe life-
threatening syndrome, a spectrum that likely reflects a combi-
nation of the degree of excess serotonergic activity in the CNS, 
or the particular 5-HT receptor subtype(s) that is (are) acti-
vated (directly or indirectly). Given the difficulty in determin-
ing the exact point at which serotonergic signs associated with 
therapeutic drug administration meet the criteria for SS, has 
led some experts in the field to prefer the use of the term sero-
tonin toxicity, as they feel this more accurately represents the 
wide range of clinical features of varying severity.18,41 
Traditionally, it is said that, in contrast to the onset of NMS, 
symptoms in SS usually begin within 24 hours of ingestion of 
the causative agent(s) and that most patients seek medical 
advice within 6 hours.11 However, these claims appear to be 
based on one review of 41 cases of SS from 1995 to 1999,12 and 
in a more recent meta-analysis, just more than 60% presented 
within 6 hours of ingestion (usually where pro-serotonergic 
drugs were administered quickly or in large doses including 
overdose), while around one quarter of patients presented later 
than 24 hours (usually when medication were more gradually 
titrated and/or cross-tapered).20 This temporal disparity may 
depend on the context in which the syndrome occurs, as well as 
pharmacokinetic and dynamic factors; an example would be 
the delayed onset of linezolid-associated SS in the elderly.98
The classic triad of clinical features (Figure 2) are altered 
mental status (including anxiety, agitation, and confusion), 
autonomic nervous system overactivity (including diaphoresis, 
tachycardia, hyperthermia, hypertension, vomiting, and diar-
rhoea), and neuromuscular hyperactivity (muscle rigidity, 
hyperkinesis including myoclonus and tremor, hyperreflexia, 
and bilateral Babinski sign).12 The acute onset of these features 
should alert the physician to the potential diagnosis, and trig-
ger a search for a toxic cause, while also excluding other mimics 
such as encephalitis (infectious or autoimmune), alcohol and/
or drug withdrawal, epileptic, and nonepileptic seizures.8 In 
milder cases, the patients are usually normothermic, with mild 
autonomic symptoms and neuromuscular signs. In moderate 
SS, in addition to hyperthermia (>40°C), patients usually 
Figure 2. The spectrum of clinical features in serotonin syndrome. gCS indicates glasgow Coma Scale.
Source: Buckley et al.8
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develop eye movement abnormalities, agitation, pressured 
speech, and hypervigilance. Patients may also startle easily or 
develop an unusual movement disorder characterised by repeti-
tive head rotation with the neck held in moderate extension.7 
In severe cases, as well as the above features, patients usually 
have a temperature greater than 41.1°C, haemodynamic/auto-
nomic instability, hyperactive bowel sounds, delirium, and 
muscle rigidity. Complications in severe cases include seizures, 
renal failure, metabolic acidosis, rhabdomyolysis, disseminated 
intravascular coagulation, acute respiratory distress syndrome, 
respiratory failure, and even death.7 Interestingly, the hyperre-
flexia and clonus are usually more prominent in the lower 
limbs,7 and this gives a clue as to the underlying diagnosis.
Diagnosis
Serotonin syndrome is a diagnosis of exclusion with no single 
diagnostic test that confirms the syndrome.7,11,99 It is an 
abstract construct combining various concepts, clinical signs, 
and symptoms that aims to relate signs of CNS hyperexcitabil-
ity with purported drug-induced serotonin excess.20 Given the 
protean ways that CNS hyperexcitability can present, com-
bined with the ability of multiple nonserotonergic pathways to 
manifest similar symptoms, makes it difficult to establish a 
gold standard to confirm SS. A plausible diagnosis of SS can 
therefore only be made when there is a high Bayesian prior 
probability (high index of clinical suspicion) in the setting of 
starting, increasing (or overdose) of a relevant serotonergic 
drug, or shortly after a second serotonergic drug is added.8 
Linked to this, it is critically important that there is a strict 
definition for what is classed as a serotonergic drug; namely, it 
causes a generalised increase in endogenous 5-HT and/or acti-
vates 5-HT receptors directly or indirectly, as well as producing 
clinical signs that are specific for SS.18
Therefore, a diagnosis of SS is entirely clinical, based on a 
careful history and examination, with a detailed enquiry about 
the use of prescription, over-the-counter, and illicit drugs 
(stimulants such as cathinones and other synthetic stimulants, 
ecstasy, amphetamines, or cocaine), as well as any dietary sup-
plements (such as St John’s wort, ginseng, tryptophan, and 
pharmaceutical adulterants in appetite suppressants).7,8 The 
rate of change of symptoms from onset, as well as development 
of new symptoms should also be reviewed. The presence of cer-
tain comorbidities, including long-term pain and depression, 
should alert to the clinician to the possibility of the use of sero-
tonergic drugs,11 and the presence of renal disease may predis-
pose those on certain SSRIs (such as sertraline) to developing 
SS.100 The clinical examination should focus on eliciting any 
signs of muscle rigidity, increased deep-tendon reflexes, as well 
as autonomic signs such as the presence of diaphoresis, 
increased bowel sounds, and mydriasis.7 There must be a high 
index of suspicion for the diagnosis in patients with any com-
bination of the aforementioned classical clinical features and a 
supporting drug history, so treatment can be rapidly initiated 
to prevent the morbidity and mortality associated with this 
condition. Misdiagnosis can be an issue however; in severe 
cases, SS can be confused with NMS, while the nonspecific 
symptoms in mild cases can be confused with other causes such 
as infection. Symptoms such as anxiety and akathisia can be 
misattributed to the patient’s mental state, while hypertension, 
diarrhoea, or tremor can easily be dismissed as part of a sys-
temic or metabolic disorder unrelated to drug therapy.101
There are 3 diagnostic classification systems available, the 
Sternbach (SC), Radomski (RC), and Hunter Serotonin 
Toxicity Criteria (HSTC), all of which try to reflect symptoms 
and symptom constellations that are felt to be characteristic of 
serotonin toxicity and therefore SS. The most recent and com-
monly used criteria are the HSTC, which are set of decision 
rules that focus on the classic features of generalised clonus 
(inducible, spontaneous, and ocular), agitation, diaphoresis, 
tremor, and hyperreflexia41 (Figure 3). Spontaneous clonus is 
Figure 3. The Hunter Serotonin Toxicity Criteria: for diagnosing serotonin syndrome. Note that the requirement for the presence of some form of 
neuromuscular excitation, the sine qua non for a diagnosis of serotonin syndrome. *The presence of temperature ⩾38.5°C and/or marked hypertonia or 
rigidity (especially truncal) indicates severe SS with a risk of progression with respiratory compromise.
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characterised by rhythmic, large muscle contractions (which 
helps to differentiate it from myoclonic jerks), and as is often 
triggered by minor movement. Ocular clonus refers to abnor-
mal involuntary, fine or coarse, oscillatory eye movements that 
can either be continuous or triggered by eye movement.8 Rarer 
eye movements seen include periodic alternating gaze devia-
tion (so-called ‘ping-pong’ gaze).8
Compared to the original SC the HSTC are simpler to use, 
more sensitive (84% vs 75%), and marginally more specific 
(97% vs 96%).41 A recent study analysing SS using a systematic 
bioinformatics approach applied to the FAERS database, 
found that the number of identified SS cases varied consider-
ably depending on which diagnostic criteria were used.19 The 
SC identified an additional 1140 cases suggesting that they 
may indeed be less specific compared to the HSTC and likely 
picks up milder cases where off-target neurotransmitter effects 
contribute to a broader nonspecific toxicity presentation.19 It 
should be noted, however, that the purported superiority of the 
HSTC is based on one study only.20 Other criticisms of the 
HSTC include their validity/generalisability to nonoverdose 
cases, given the criteria were derived solely from single SSRI 
overdoses; that a percentage of the cases in the derivation data 
set was also present in the test data set in the original study, 
which could potentially lead to an overestimation of the valid-
ity of the criteria20; and finally that they may not perform well 
in patients with concomitant neurological disease. The cardinal 
signs of hyperreflexia and clonus may be masked, both in 
patients with peripheral neuropathy,102 as well as those with 
severe SS who have substantial muscle rigidity.7
In addition to truncal rigidity, in severe, life-threatening 
cases of SS rapidly rising temperatures above 38°C and periph-
eral hypertonicity are usually key features. Investigations are of 
little diagnostic value, though are useful to help identify com-
plications of hyperthermia and muscle rigidity (rhabdomyoly-
sis, disseminated intravascular coagulation, and multiorgan 
failure); abnormalities that are often seen include elevated cre-
atine kinase, liver enzymes, deranged renal function, and low 
bicarbonate levels.11 It is important to also exclude cardiologi-
cal effects of drugs in overdose with an electrocardiogram 
(ECG), as well as alternative diagnoses such as encephalitis 
and cerebral vasculitis, where relevant, with magnetic reso-
nance imaging (MRI), electroencephalogram (EEG), and lum-
bar puncture.18 In intentional overdoses, a toxicology screen 
should be sent including for paracetamol and salicylates. There 
is no role for testing of blood concentrations of serotonin, as 
there is no correlation with clinical severity.12
Differential diagnosis
The differential diagnosis for SS includes other toxidromes 
such as NMS, malignant hyperthermia, and anticholinergic 
toxicity (Table 3), as well conditions such as meningitis, 
encephalitis (in particular autoimmune encephalitis), central 
hyperthermia, and heatstroke.
Table 3. Differentiating serotonin syndrome from other toxidromes.
TOxIDROME CAUSATIVE 
AgENT
ONSET, 
RESOLUTION
VITAL SIgNS PUPILS MENTAL STATE OTHER CLINICAL 
FEATURES
Serotonin 
syndrome
Serotonergic 
drugs
Sudden <24 h
Most resolve with 
24 h with treatment 
(though 25% 
develop symptoms 
after >24 h)
Hyperthermia 
(>41.1°C), 
tachycardia, 
hypertension, and 
tachypnoea
Mydriasis Delirum, 
agitation, and 
coma
Neuromuscular 
hyperactivity (tremor, 
myoclonus, hyperreflexia, 
and clonus), diaphoresis, 
and hyperactive bowel 
sounds
Neuroleptic 
malignant 
syndrome
Dopamine 
antagonists and 
dopamine 
withdrawal
Slower onset (days 
to weeks)
Up to 10 days to 
resolve with 
treatment
Hyperthermia 
(>41.1°C), 
tachycardia, 
hypertension, and 
tachypnoea
Normal or 
mydriasis
Delirium, 
agitation
Neuromuscular 
hypoactivity (‘lead-pipe’ 
rigidity and bradykinesia)
Hypoactive bowel sounds
Anticholinergic 
toxicity
Anticholinergic 
agents
Sudden <24 h
Resolves hours to 
days with treatment
Hyperthermia 
(usually <38.8°C), 
tachycardia, 
hypertension 
(mild), and 
tachypnoea
Mydriasis Hyper-
vigilance, 
agitation, 
hallucination, 
delirium with 
mumbling 
speech, and 
coma
Normal muscle tone and 
reflexes
Dry flushed skin and 
mucous membranes
Hypoactive bowel sounds 
Urinary retention 
Hyperkinesis (myoclonus, 
choreoathetosis, and 
picking behaviour) 
Seizures (rare)
Malignant 
hyperthermia
Inhalational 
anaesthetics and 
depolarising 
muscle relaxants 
(succinylcholine)
Very sudden (mins 
to hours)
Resolves 24-48 h 
with treatment
Hyperthermia 
(can be as high as 
46°C), 
tachycardia, 
hypertension, and 
tachypnoea
Normal Agitation Rigour-mortis like rigidity 
Hyporeflexia
Hypoactive bowel sounds
Rising end-tidal CO2
Mottled skin with flushing 
and cyanosis
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Neuroleptic malignant syndrome is a fulminant and life-
threatening idiosyncratic drug reaction to therapeutic doses of 
dopamine antagonists. Although the exact pathophysiology is 
not completely understood, central dopaminergic blockade is 
thought to play a pivotal role, with sympathoadrenal dysfunc-
tion also potentially involved.103 Although NMS is often con-
fused with SS, a detailed history focusing on time course of 
onset and medication usage, examination findings and clinical 
course allow differentiation of the 2 conditions. While SS is 
characterised by neuromuscular hyperactivity (hyperreflexia 
with clonus, myoclonus, and tremor), in NMS, there is usually 
decreased neuromuscular activity with extrapyramidal features 
(hypokinesia and lead-pipe rigidity). Importantly in NMS, 
hyperreflexia and clonus are rarely feature104 something 
reflected in the primacy of clonus in establishing a diagnosis of 
SS in the HTSC.41 Established orthodoxy is that NMS devel-
ops over days to weeks while SS develops more rapidly (usually 
within 24 h), though this has been challenged recently by a 
group that have shown that 25% of patients in their study 
developed SS later than 24 hours after ingestion of the causa-
tive agent.20 In those patients where serotonergic medications 
were gradually titrated and cross-tapered, the percentage pre-
senting after 24 hours increased to more than 60.4%. 
Hyperthermia, muscle rigidity, altered mental status, rhabdo-
myolysis, and deranged blood tests (leucocytosis, elevated 
hepatic transaminases, elevated creatine kinase, and metabolic 
acidosis) can be seen in severe cases of both syndromes. Care 
must therefore be taken in weighting the diagnosis too heavily 
based these findings as well as speed of onset.
In anticholinergic toxicity, muscular tone and reflexes are 
normal, with hypoactive bowel sounds and dry, erythematous 
skin; all features that help distinguish it from SS. They classi-
cally present in addition with hyperthermia, agitation, altered 
mental status, dry mucous membranes, and mydriasis.18
Malignant hyperthermia occurs in genetically susceptible 
individuals within minutes of exposure to inhalational halo-
genated anaesthetic agents and depolarising muscle relaxants 
(such as succinylcholine). The syndrome is characterised by 
hyperthermia, tachycardia, rigour-mortis-like muscle rigidity, 
metabolic acidosis, and increasing concentrations of end-tidal 
carbon dioxide.105
With regards to the other differential diagnoses, SS can 
usually be distinguished from them based on increased neuro-
muscular activity; patients with CNS infections or sympatho-
mimetic toxidromes are less likely to exhibit this increased 
activity.106
Management
The 2 main components for optimal management of SS are 
first good supportive care (especially in severe cases) and sec-
ond risk assessment and close monitoring of those with mild to 
moderate SS to avoid progression to severe life-threatening 
SS.18 The first step is to identify and stop the offending sero-
tonergic medication(s), with supportive care to stabilise vital 
signs (maintenance of oxygen saturations, intravenous fluids, 
and continuous temperature cardiac monitoring), sedation 
with benzodiazepines (such as diazepam or midazolam), and in 
more severe cases, consideration of serotonin antagonists 
alongside muscle paralysis. When paralysis is indicated, strong 
consideration should be given to the initiation of continuous 
EEG, if available, to assess for electrographic seizure activity 
that cannot be clinically manifest while chemically paralysed. 
Alongside early recognition, it is essential the clinician recog-
nises the potentially rapid rate of progression of SS and insti-
gates immediate aggressive treatment in those who were 
previously being treated conservatively that deteriorate.7,13,107
The intensity of treatment depends on the severity of the 
toxicity (Figure 2). In mild cases, discontinuation of the 
offending medication, sedation with benzodiazepines and 
supportive care is often sufficient, whereas in moderate SS, 
there needs to be more aggressive treatment of haemody-
namic/autonomic instability with consideration of adding in a 
serotonin antagonist (such as cryproheptadine). Severe SS is a 
medical emergency often complicated by severe hyperthermia, 
rhabdomyolysis, disseminated intravascular coagulation, and 
acute respiratory distress syndrome (ARDS), requiring seda-
tion, muscle paralysis, and intubation in the intensive care set-
ting.106 Most cases of SS usually resolve with 24 to 72 hours, 
though this may take longer in those on drugs with longer 
elimination half-lives, active metabolites, or a longer duration 
of action.7 Irreversible MAOIs carry the greatest risk with 
symptoms lasting for several days, while patients can still be at 
risk of SS up to several weeks after the discontinuation of 
SSRIs. Fluoxetine is a particular risk, with a half-life as long as 
7 days after long-term admission and its metabolite norfluox-
etine up to 2.5 weeks.108
Agitation
Chemical restraint is preferred to sedating agitated patients, 
due to the risk of severe lactic acidosis and hyperthermia from 
physical restraints causing isometric muscle contractions. Of 
the sedating agents, benzodiazepines are commonly used first 
line; not only do they control agitation, but they also blunt the 
hyperadrenergic component, helping to correct mild increases 
in blood pressure and heart rate.107 There is evidence in animal 
models of SS that pretreatment with diazepam and chlorme-
thiazole prolongs survival,55 though there is no evidence cur-
rently in humans. Clinicians should titrate the benzodiazepine 
to clinical effect, with the goal of patient sedation and mainte-
nance of normal vital signs.106
Autonomic instability
In severe SS, patients can often have large and rapid changes in 
heart rate and blood pressure, making management difficult.7 
If benzodiazapines are not sufficient to lower blood pressure, 
then patients should be treated with short-acting agents such 
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as esmolol or nitroprusside.41 Longer acting agents such as 
propranolol, which can cause hypotension and mask tachycar-
dia (a sign which is useful in monitoring patient response and 
improvement), should be avoided.7,41 Hypotension can be a 
particular problem in those patients who have taken MAOIs, 
and preferred treatment in this situation is with low doses of 
direct-acting sympathomimetic amines (such as norepineph-
rine, epinephrine, or phenylephrine).7 Indirect sympathomi-
metic agents such as dopamine should be avoided, due to 
theoretical risk of an exaggerated haemodynamic response in 
the setting of MAOI inhibition.
Hyperthermia
In severe SS, preventing hyperthermia and consequent multi-
organ failure is a key goal. Lowering temperature in animal 
models has also been shown to indirectly downregulate 
5-HT2A receptors in the CNS and reduce overall serotonin 
levels.109 Given the increase in body temperature in these 
patients is due to an increase in muscular activity, rather than 
an increase in the hypothalamic set point (that is seen in 
pyrexia), antipyretic agents have little effect and are not indi-
cated.7,48 Key components of management include sedation 
(oral diazepam or a midazolam infusion) to reduce muscle 
activity, active cooling (including fans, water sprays, ice packs, 
cooled crystalloids, or cooling blankets), and in severe cases 
muscle paralysis and ventilation on the intensive care unit 
(ITU). In the severe cases where the temperature is greater 
than 41.1°C, patients should be immediately paralysed and 
intubated, with nondepolarizing agents such as vecuronium to 
maintain paralysis. It is important for clinicians to be aware 
that in rare cases succinylcholine can worsen rhabdomyolysis 
and put the patient at risk of hyperkalaemic-induced arryth-
mias.7 Fentanyl should also be avoided due its serotonergic 
effect. Adequate sedation with a benzodiazepine while the 
patient is paralysed should be maintained. The optimum tim-
ing for stopping of neuromuscular paralysis is not currently 
known, but there is evidence from case reports that premature 
termination can lead to recrudescence of the hyperthermia7; as 
such, the clinician should anticipate this rebound and have a 
low threshold for restarting muscle paralysis.
Antidote(s)
If the use of the aforementioned strategies fails to control the 
agitation and correct vital signs, then there is some evidence for 
the use of serotonin antagonists. Animal studies have suggested 
that 5-HT2A receptor antagonists may reduce hyperthermia 
and other severe manifestations of SS.18,109,110 Both chlor-
promazine and cyproheptadine in high doses have been used, 
though given chlorpromazine can cause severe hypotension, as 
well as case reports that antipsychotics can themselves precipi-
tate SS, means cyproheptadine is usually favoured first line.106 
There is some evidence from case reports that support its role 
in reducing symptoms in mild to moderate SS, though there its 
role in severe SS is less clear.111-115 Cyproheptadine is a hista-
mine-1 receptor antagonist with nonspecific 5-HT1A, 5-HT2A, 
5-HT2B, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptor antago-
nistic properties as well as some weak anticholinergic effects.111 
The purported role of 5-HT2A antagonism in mediating 
cyproheptadine’s beneficial effect is interesting, given that there 
appears to be an association between 5-HT2A antagonists 
themselves in the form of SGAs and the risk of SS.43 Given 
that it antagonises a number of different serotonin receptors in 
addition to 5-HT2a, it may be that concomitant antagonism of 
5-HT1A receptors (as well as others) at higher doses accounts 
for this apparent contradiction, though evidence for this is cur-
rently lacking.
An initial loading dose of 12 mg orally or crushed via a 
nasogastric tube is recommended, followed by 2 mg every 
2 hours until clinical improvement is seen.11 An alternative 
dosing regimen involves switching to 8 mg every 6 hours once 
symptoms are controlled.7 Cyproheptadine is only available in 
an oral form, but the tablets may be crushed and given through 
a nasogastric or orogastric tube. It can cause a decrease in vas-
cular tone with a consequent transient hypotension, though 
this is usually responsive to intravenous fluids.
Historically, therapeutics targeting the serotonergic system 
centrally have been focused on 5-HT transporters and recep-
tors, to modulate conditions such as depression, migraine, or 
psychosis.116-118 There is currently a lack of novel therapeutics 
targeting serotonin synthesis in the CNS, drugs which if devel-
oped, might offer a therapeutic option in SS. An interesting 
avenue of research comes from work in the carcinoid syndrome. 
Carcinoid syndrome describes a constellation of clinical symp-
toms including diarrhoea, wheezing, bronchoconstriction, 
cutaneous flushing, cardiac valve disease, and mesenteric fibro-
sis.119 It is usually caused by neuroendocrine tumours, a clini-
cally and genetically heterogeneous group of GI, bronchial, and 
more rarely pancreatic, kidney, or ovarian tumours. These 
tumours can release a cocktail of vasogenic amines (predomi-
nantly 5-HT), as well as prostaglandins, and other polypep-
tides which induce the clinical syndrome. Gastrointestinal 
NETs account for up to 80% of cases of carcinoid syndrome 
usually in the setting of hepatic metastases.120 The inability of 
5-HT to cross the blood brain barrier opens up the opportu-
nity to pharmacologically target the central and peripheral 
5-HT systems independently. Since the functional classifica-
tion of TPH isoforms in 2003,28 TPH1, the peripheral iso-
form, has been established as a pharmacological target for the 
treatment of peripheral 5-HT-associated diseases such as 
carcinoid. Early inhibitors developed to treat carcinoid syn-
drome, the low molecular weight phenylalanine analogues 
p-chlorophenylalanine (fenclonine, PCPA) and p-ethynylphe-
nylalanine (PEPA), showed promise in terms of lowering 
peripheral 5-HT. However irreversible inhibition of TPH2 
centrally, limited their therapeutic use, due to the significant 
reduction in brain 5-HT concentrations.121-123 This off-target 
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effect may however offer an opportunity to develop specific, 
reversible TPH2 inhibitors that could play a role in treatment 
of SS, through inhibition of synthesis leading to depletion of 
endogenous CNS serotonin. More recently, reversible TPH 
inhibitors such as telotristat (Masib) derived from administra-
tion of the relatively inactive prodrug telotristat ethyl have been 
developed. Telotristat is indicated in combination with soma-
tostatin analogues (eg, octreotide) for the treatment of diar-
rhoea in carcinoid patients. Due to significant active-site 
structural homology, telotristat inhibits both TPH1 and TPH2 
with similar affinity in vitro, yet the inability to penetrate the 
blood-brain barrier prevents reduction in central serotonin 
levels.28
Prognosis
As emphasised previously, the SS is a spectrum of dose-
dependent clinical features ranging from very mild to life-
threatening severe toxicity. Prognosis is generally favourable if 
the syndrome is recognised early, the causative agent is stopped, 
and complications are treated. This requires the clinician to 
have a high clinical suspicion for SS, and even if the diagnosis 
is unclear, discontinue any serotonergic agents and start sup-
portive care. In severe cases, aggressive management on ITU is 
required, whereas those with moderate features need admitting 
for observation and vital system monitoring until symptoms 
resolve, with a low threshold for escalating management should 
there be any early signs of deterioration. These patients can 
usually be monitored for up to 6 hours, and if vital signs and 
mental state remain normal, with no evidence of neuromuscu-
lar hyperexcitability (in particular clonus or hyperreflexia), then 
they can be discharged home with close follow-up.106 In most 
cases of SS, symptoms usually resolve within 24 hours of stop-
ping the drug, though in a minority of cases where the drug has 
active metabolites or a longer half-life, symptoms can last for 
longer than this.7 In milder cases, it is necessary for the clini-
cian, in close collaboration with the patient, to weigh up risks 
and the benefits to decide whether the patient should restart 
the serotonergic agent (preferably at a lower dose).
Prevention
Prevention of SS requires a multitiered approach including 
education of both physicians and patients regarding potent 
serotonergic drug interactions, and the clinical signs and symp-
toms of SS to look out for, modification of prescribing practices 
to integrate automated e-prescribing algorithms to flag poten-
tial drug interactions, and ongoing pharmacogenetic research.
Although there are numerous systematic reviews focused 
on identifying which drug interactions can precipitate severe 
SS,63,124-128 there has been a proliferation in spurious drug 
associations, in part driven by the nonspecific clinical features 
in milder forms of the condition, and a (some might argue 
too) broad definition of what entails a serotonergic agent.8 
Currently, clinicians prescribing an SSRI, or patients looking 
for information online, can be presented with up to 1000 
interacting drugs, with a significant number of these warning 
of the potential for SS. While some of these interactions are 
potentially lethal and should be avoided (for example, SSRIs 
and MAOIs),8 many are likely to only result in minor effects, 
and for some drugs (including carbamazepine, triptans,127 
most tricyclic antidepressants [TCAs], and atypical antide-
pressants),63,129 there is no or little evidence to support pre-
cipitating SS with coadministration. For the diagnosis of SS 
to be clinically meaningful, if the classification of a serotoner-
gic agent is broadened to include any agent that has any mod-
ulatory effect on the serotonergic system in the CNS, then 
the clinical features need to be highly specific for the condi-
tion. Conversely, if we accept that the clinical features in the 
current criteria do not meet this threshold of specificity, then 
there must be evidence with a particular drug, or combination 
of drugs, that they directly lead to excessive serotonergic 
activity18 rather than simply a poorly defined modulatory 
action on the serotonergic pathway. Ongoing drug surveil-
lance to identify potent serotonergic effects and integration of 
the results into physician and patient education is also critical, 
both to maintain awareness and also to keep these groups 
abreast of developments in the field.21 Patients also need to be 
aware that over-the-counter medications and herbal reme-
dies, such as St John’s wort, can have serotonergic activity and 
can lead to serious interactions with prescribed serotonergic 
drugs such as SSRIs and MAOIs.8
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